The global HPV testing and Pap test market size was estimated at USD 3.34 billion in 2024 and is projected to reach USD 6.18 billion by 2033, growing at a CAGR of 7.2% from 2025 to 2033. Technological advancements in testing products, increasing prevalence of cervical cancer, and government initiatives to reduce disease burden are some of the key factors driving the market growth over the forecast period.
Cervical cancer remains a critical health issue for women worldwide. In March 2024, the WHO published a fact sheet showing that approximately 660,000 women were diagnosed with cervical cancer in 2022, and about 350,000 women died from it. The highest incidence and mortality rates are found in low- and middle-income countries, particularly in sub-Saharan Africa, Central America, and Southeast Asia, where disparities in access to vaccination, screening, and treatment continue to drive this significant health burden.
Making screening and early detection must remain at the forefront of public health planning. At the root of much of this burden lies the human papillomavirus (HPV). A meta-analysis and systematic review published by the Technical University of Munich in January 2025 found that in women aged 50 and older with normal cytology, the pooled global prevalence of any HPV was 11.70% and the prevalence of high-risk HPV types was 6.45%. The high prevalence of HPV infection highlights the large population eligible for screening and emphasizes the critical role of HPV testing in cervical cancer prevention programs. Given that persistent HPV infection is the leading cause of cervical cancer, incorporating reliable HPV tests alongside Pap test is increasingly essential.
Favorable initiatives undertaken by governments for cervical cancer screening of women in the average-to-high-risk group are further anticipated to drive the market. Some of the guideline committees are ACS, the U.S. Preventive Services Task Force (USPSTF), the American Society for Colposcopy and Cervical Pathology (ASCCP), the American College of Obstetricians and Gynecologists (ACOG), and the Society of Gynecologic Oncology (SGO) is continuously increasing awareness about the disease among people. Moreover, in May 2023, the National Cervical Screening Program (NCSP) of Australia updated guidelines to prevent cervical cancer by increasing screening of women aged between 25 to 74 years.
An increase in awareness programs for screening by organizations including National Cervical Cancer Coalition (NCCC), WHO, CDC, and USPSTF is one of the major factors expected to boost market growth during the forecast period. For instance, in January 2023, the WHO launched the Cervical Cancer Elimination Strategy for the Eastern Mediterranean region and announced January as a Cervical Cancer Awareness month. Under this program, the WHO set the target to screen 70% of women aged 35 to 45 years. In addition, major market players are undertaking initiatives to increase awareness about cervical and vaginal cancer screening to detect diseases at an early stage.
The introduction of technologically advanced testing products and guidelines for utilizing novel tests is expected to further increase market growth over the forecast period. Market players are expanding their R&D activities to introduce novel and effective HPV tests for diagnosing infections. In March 2025, WHO prequalified the Alinity m HR HPV diagnostic test by Abbott, which detects DNA from 14 high-risk HPV genotypes, including genotypes 16, 18, and 45. The test's results, combined with clinical assessment and guidelines, can help guide patient management.
This product will be delivered within 1-3 business days.
Cervical cancer remains a critical health issue for women worldwide. In March 2024, the WHO published a fact sheet showing that approximately 660,000 women were diagnosed with cervical cancer in 2022, and about 350,000 women died from it. The highest incidence and mortality rates are found in low- and middle-income countries, particularly in sub-Saharan Africa, Central America, and Southeast Asia, where disparities in access to vaccination, screening, and treatment continue to drive this significant health burden.
Making screening and early detection must remain at the forefront of public health planning. At the root of much of this burden lies the human papillomavirus (HPV). A meta-analysis and systematic review published by the Technical University of Munich in January 2025 found that in women aged 50 and older with normal cytology, the pooled global prevalence of any HPV was 11.70% and the prevalence of high-risk HPV types was 6.45%. The high prevalence of HPV infection highlights the large population eligible for screening and emphasizes the critical role of HPV testing in cervical cancer prevention programs. Given that persistent HPV infection is the leading cause of cervical cancer, incorporating reliable HPV tests alongside Pap test is increasingly essential.
Favorable initiatives undertaken by governments for cervical cancer screening of women in the average-to-high-risk group are further anticipated to drive the market. Some of the guideline committees are ACS, the U.S. Preventive Services Task Force (USPSTF), the American Society for Colposcopy and Cervical Pathology (ASCCP), the American College of Obstetricians and Gynecologists (ACOG), and the Society of Gynecologic Oncology (SGO) is continuously increasing awareness about the disease among people. Moreover, in May 2023, the National Cervical Screening Program (NCSP) of Australia updated guidelines to prevent cervical cancer by increasing screening of women aged between 25 to 74 years.
An increase in awareness programs for screening by organizations including National Cervical Cancer Coalition (NCCC), WHO, CDC, and USPSTF is one of the major factors expected to boost market growth during the forecast period. For instance, in January 2023, the WHO launched the Cervical Cancer Elimination Strategy for the Eastern Mediterranean region and announced January as a Cervical Cancer Awareness month. Under this program, the WHO set the target to screen 70% of women aged 35 to 45 years. In addition, major market players are undertaking initiatives to increase awareness about cervical and vaginal cancer screening to detect diseases at an early stage.
The introduction of technologically advanced testing products and guidelines for utilizing novel tests is expected to further increase market growth over the forecast period. Market players are expanding their R&D activities to introduce novel and effective HPV tests for diagnosing infections. In March 2025, WHO prequalified the Alinity m HR HPV diagnostic test by Abbott, which detects DNA from 14 high-risk HPV genotypes, including genotypes 16, 18, and 45. The test's results, combined with clinical assessment and guidelines, can help guide patient management.
Global HPV Testing and Pap Test Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global HPV testing and Pap test market report based on type, application, product, technology, end use, and region:Type Outlook (Revenue, USD Million, 2021-2033)
- Pap Test
- HPV Test
Application Outlook (Revenue, USD Million, 2021-2033)
- Cervical Cancer Screening
- Vaginal Cancer Screening
Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments
- Consumables
- Services
Technology Outlook (Revenue, USD Million, 2021-2033)
- PCR
- Immunodiagnostics
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Laboratories
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. HPV Testing And Pap Test Variables, Trends & Scope
Chapter 4. HPV Testing And Pap Test: Product Estimates & Trend Analysis
Chapter 5. HPV Testing And Pap Test: Application Estimates & Trend Analysis
Chapter 6. HPV Testing And Pap Test: Product Estimates & Trend Analysis
Chapter 7. HPV Testing And Pap Test: Technology Estimates & Trend Analysis
Chapter 8. HPV Testing And Pap Test: End Use Estimates & Trend Analysis
Chapter 9. HPV Testing And Pap Test: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this HPV Testing and Pap Test market report include:- Abbott.
- QIAGEN
- BD.
- Quest Diagnostics Incorporated
- Hologic, Inc.
- F. Hoffmann-La Roche Ltd
- Femasys Inc.
- Arbor Vita Corporation
- NURX Inc.
- Seegene Inc.
- Thermo Fisher Scientific Inc.
- BIOMÉRIEUX S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 3.34 Billion |
| Forecasted Market Value ( USD | $ 6.18 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
